Antibodies against the immune checkpoint receptors, such as programmed cell death protein 1 (PD-1), PD-1 ligand (PD-L1/2), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), can be used to counteract the immune checkpoint modulation in melanoma. This evidence concerns the gene CTLA4 and melanoma.